Full Press Release Details
ATEC Reports Third Quarter 2022 Financial Results
Total revenue grew 43% to $90 million, including surgical revenue growth of 53%
EOS revenue of $11 million
Adjusted EBITDA improved significantly, both year-over-year and sequentially
CARLSBAD, Calif., November 3, 2022 Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2022, and recent corporate highlights.
Third Quarter and Full-Year 2022 Financial Results
| Quarter Ended September 30, 2022 | |
| Total revenue | $90 million |
| GAAP gross margin | 66% |
| Non-GAAP gross margin | 71% |
| Operating expenses | $94 million |
| Non-GAAP operating expenses | $78 million |
| GAAP operating loss | ($35) million |
| Non-GAAP adjusted EBITDA | ($6) million |
| Ending cash balance | $106 million |
-Enhanced lateral sophistication from L3 to S1, applying learnings from the prone transpoas (PTP ) approach to evolve the lateral transpsoas (LTP ) procedure and develop a Midline ALIF approach;
-Launched ATEC's first expandable interbody and Sigma Medialized access technology to advance the minimally-invasive (MIS) posterior approach, which can integrate with PTP to address L5-S1;
-Drove a 32% increase in surgical volume and a 22% increase in users compared to prior year, and hosted approximately 150 surgeons at training events;
-Achieved operating cost leverage with adjusted EBITDA margin increasing approximately 870 basis points compared to prior year and approximately 290 basis points sequentially;
-Closed $50 million revolving credit facility with $25 million accordion feature.
We are executing on our innovation and financial commitments and I am confident we can continue to do so in the years ahead, said Pat Miles, Chairman and Chief Executive Officer. During the third quarter, ATEC's Organic Innovation Machine introduced multiple outcome-improving approaches and technologies, which were enthusiastically received. It is increasingly clear: surgeons are buying in to our clinical thesis which will go well beyond lateral.
Financial Outlook for the Full-Year 2022
The Company expects total revenue of $340 million for the fiscal year ended December 31, 2022, in line with the 40% full-year growth rate previewed in conjunction with the release of preliminary third quarter financial results. This includes surgical revenue growth of approximately 39% and $46 million of EOS revenue.
Financial Results Webcast
ATEC will present these results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET. The live webcast can be accessed by visiting the Investor Relations Section of ATEC's Corporate Website.
To dial in to the webcast, please register via this link.
A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. In addition, a dial-in replay will be available beginning two hours after the webcast's completion through November 10, 2022. Access the replay by dialing (800) 770-2030 and referencing conference ID number 97241.
Non-GAAP Financial Information
To supplement the Company's financial statements presented in accordance with generally accepted accounting principles in the United States of America (GAAP), the Company reports certain non-GAAP financial measures, including non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating loss, and non-GAAP adjusted EBITDA. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company's non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.
About Alphatec Holdings, Inc.
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the Company's expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue, balance sheet, growth and financial outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; and the Company's future ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third-party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; and the Company's ability to meet its financial obligations. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
Investor/Media Contact:
Chief Financial Officer
ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (unaudited) | ||||||||||||||||
| Revenue: | ||||||||||||||||
| Revenue from products and services | $ | 89,839 | $ | 62,735 | $ | 244,908 | $ | 168,336 | ||||||||
| Revenue from international supply agreement | 145 | 15 | 914 | |||||||||||||
| Total revenue | 89,839 | 62,880 | 244,923 | 169,250 | ||||||||||||
| Cost of sales | 30,323 | 23,266 | 80,715 | 56,713 | ||||||||||||
| Gross profit | 59,516 | 39,614 | 164,208 | 112,537 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 12,111 | 9,391 | 32,429 | 23,031 | ||||||||||||
| Sales, general and administrative | 75,954 | 61,494 | 218,093 | 162,578 | ||||||||||||
| Litigation-related expenses | 3,602 | 1,209 | 16,629 | 5,711 | ||||||||||||
| Amortization of acquired intangible assets | 2,774 | 2,012 | 7,181 | 3,392 | ||||||||||||
| Transaction-related expenses | 373 | 120 | 6,156 | |||||||||||||
| Restructuring expenses | 45 | 256 | 1,704 | 1,587 | ||||||||||||
| Total operating expenses | 94,486 | 74,735 | 276,156 | 202,455 | ||||||||||||
| Operating loss | (34,970 | ) | (35,121 | ) | (111,948 | ) | (89,918 | ) | ||||||||
| Interest and other expense, net: | ||||||||||||||||
| Interest expense, net | (1,285 | ) | (1,272 | ) | (4,176 | ) | (5,604 | ) | ||||||||
| Loss on debt extinguishment, net | (7,434 | ) | (7,434 | ) | ||||||||||||
| Other (expense) income, net | (615 | ) | 886 | (578 | ) | (1,020 | ) | |||||||||
| Total interest and other expense, net | (1,900 | ) | (7,820 | ) | (4,754 | ) | (14,058 | ) | ||||||||
| Net loss before taxes | (36,870 | ) | (42,941 | ) | (116,702 | ) | (103,976 | ) | ||||||||
| Income tax provision | 129 | 90 | 461 | 163 | ||||||||||||
| Net loss | $ | (36,999 | ) | $ | (43,031 | ) | $ | (117,163 | ) | $ | (104,139 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.35 | ) | $ | (0.43 | ) | $ | (1.14 | ) | $ | (1.09 | ) | ||||
| Weighted average shares outstanding, basic and diluted | 104,804 | 99,571 | 102,561 | 95,204 | ||||||||||||
| Stock-based compensation included in: | ||||||||||||||||
| Cost of sales | $ | 735 | $ | 310 | $ | 1,440 | $ | 489 | ||||||||
| Research and development | 1,653 | 1,440 | 3,987 | 2,602 | ||||||||||||
| Sales, general and administrative | 8,689 | 9,004 | 25,037 | 23,633 | ||||||||||||
| $ | 11,077 | $ | 10,754 | $ | 30,464 | $ | 26,724 |
ALPHATEC HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2022 | December 31, 2021 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 106,112 | $ | 187,248 | ||||
| Accounts receivable, net | 50,723 | 41,893 | ||||||
| Inventories | 102,159 | 91,703 | ||||||
| Prepaid expenses and other current assets | 9,718 | 10,313 | ||||||
| Total current assets | 268,712 | 331,157 | ||||||
| Property and equipment, net | 98,908 | 87,401 | ||||||
| Right-of-use assets | 28,451 | 25,283 | ||||||
| Goodwill | 37,593 | 39,689 | ||||||
| Intangible assets, net | 79,738 | 85,274 | ||||||
| Other assets | 2,881 | 3,249 | ||||||
| Total assets | $ | 516,283 | $ | 572,053 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 33,374 | $ | 25,737 | ||||
| Accrued expenses and other current liabilities | 61,741 | 55,549 | ||||||
| Contract liabilities | 12,293 | 15,255 | ||||||
| Short-term debt | 13,550 | 342 | ||||||
| Current portion of operating lease liabilities | 4,529 | 4,212 | ||||||
| Total current liabilities | 125,487 | 101,095 | ||||||
| Total long-term liabilities | 389,762 | 367,933 | ||||||
| Redeemable preferred stock | 23,603 | 23,603 | ||||||
| Stockholders' (deficit) equity | (22,569 | ) | 79,422 | |||||
| Total liabilities and stockholders' (deficit) equity | $ | 516,283 | $ | 572,053 |
ALPHATEC HOLDINGS, INC.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (unaudited) | ||||||||||||||||
| Gross profit, GAAP | $ | 59,516 | $ | 39,614 | $ | 164,208 | $ | 112,537 | ||||||||
| Add: amortization of intangible assets | 28 | 270 | 37 | 806 | ||||||||||||
| Add: stock-based compensation | 735 | 310 | 1,440 | 489 | ||||||||||||
| Add: purchase accounting adjustments on acquisitions | 347 | 2,577 | 784 | 4,340 | ||||||||||||
| Add: excess and obsolete write-down | 2,923 | 2,525 | 7,023 | 6,842 | ||||||||||||
| Non-GAAP gross profit | $ | 63,549 | $ | 45,296 | $ | 173,492 | $ | 125,014 | ||||||||
| Gross margin, GAAP | 66.2 | % | 63.0 | % | 67.0 | % | 66.5 | % | ||||||||
| Add: amortization of intangible assets | 0.0 | % | 0.4 | % | 0.0 | % | 0.5 | % | ||||||||
| Add: stock-based compensation | 0.8 | % | 0.5 | % | 0.6 | % | 0.3 | % | ||||||||
| Add: purchase accounting adjustments on acquisitions | 0.4 | % | 4.1 | % | 0.3 | % | 2.6 | % | ||||||||
| Add: excess and obsolete write-down | 3.3 | % | 4.0 | % | 2.9 | % | 4.0 | % | ||||||||
| Non-GAAP gross margin | 70.7 | % | 72.0 | % | 70.8 | % | 73.9 | % | ||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (unaudited) | ||||||||||||||||
| Operating expenses, GAAP | $ | 94,486 | $ | 74,735 | $ | 276,156 | $ | 202,455 | ||||||||
| Adjustments: | ||||||||||||||||
| Stock-based compensation | (10,342 | ) | (10,444 | ) | (29,024 | ) | (26,235 | ) | ||||||||
| Litigation-related expenses | (3,602 | ) | (1,209 | ) | (16,629 | ) | (5,711 | ) | ||||||||
| Amortization of intangible assets | (2,774 | ) | (2,012 | ) | (7,181 | ) | (3,392 | ) | ||||||||
| Transaction-related expenses | (373 | ) | (120 | ) | (6,156 | ) | ||||||||||
| Restructuring expenses | (45 | ) | (256 | ) | (1,704 | ) | (1,587 | ) | ||||||||
| Non-GAAP operating expenses | $ | 77,723 | $ | 60,441 | $ | 221,498 | $ | 159,374 | ||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (unaudited) | ||||||||||||||||
| Operating loss, GAAP | $ | (34,970 | ) | $ | (35,121 | ) | $ | (111,948 | ) | $ | (89,918 | ) | ||||
| Depreciation | 8,010 | 5,311 | 22,601 | 13,788 | ||||||||||||
| Amortization of intangible assets | 2,802 | 2,281 | 7,218 | 4,198 | ||||||||||||
| EBITDA | (24,158 | ) | (27,529 | ) | (82,129 | ) | (71,932 | ) | ||||||||
| Add back significant items: | ||||||||||||||||
| Stock-based compensation | 11,077 | 10,754 | 30,464 | 26,724 | ||||||||||||
| Purchase accounting adjustments on acquisitions | 347 | 2,577 | 784 | 4,340 | ||||||||||||
| Excess & obsolete write-down | 2,923 | 2,525 | 7,023 | 6,842 | ||||||||||||
| Litigation-related expenses | 3,602 | 1,209 | 16,629 | 5,711 | ||||||||||||
| Transaction-related expenses | 373 | 120 | 6,156 | |||||||||||||
| Restructuring expenses | 45 | 256 | 1,704 | 1,587 | ||||||||||||
| Adjusted EBITDA | $ | (6,164 | ) | $ | (9,835 | ) | $ | (25,405 | ) | $ | (20,572 | ) |